Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients (INMUNOEND) (clinicaltrials.gov) - Nov 29, 2025 - P=N/A | N=123 | Not yet recruiting | Sponsor: Maimónides Biomedical Research Institute of Córdoba | Initiation date: Aug 2025 ➔ Dec 2025
Trial initiation date • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Transplantation
|